Clinical outcomes of flupenthixol melitracen combined with conventional drugs on refractory asthma with anxiety and/or depression

Abstract

Objective To investigate the clinical outcomes of flupenthixol melitracen on refractory asthma with anxiety and/or depression. Methods 105 patients with refractory asthma, who were given asthma controlled test (ACT) and comprehensive hospital anxiety and depression scale (HAD)test, were randomly classified into control group and treatment group, the former used recommended classical drugs in the consensus, Salmeterol Xinafoate and Fluticasone Propionate and Montelukast; while the latter used above therapy combining flupentixol melitrace. HAD score, ACT score and pulmonary function were applied to assess therapeutic effect. Results In 105 cases of refractory asthma patients, 75 patients were complicated with anxiety and/or depression, with prevalence of 71.42%. With the alleviation of anxiety and/or depression, the degree of asthma controlled was improved. After treatment, HAD score of the treatment group was lower that of control group((10.67±2.32)scores vs (11.94±3.02)scores, t=2.06, P<0.05), ACT score in treatment group was much higher than that of control group((14.54±3.14)scores vs (11.25±3.06)scores, t=4.59, P<0.01), there were statistical significance in FEV1%pre between two groups((55.29±5.72)vs (43.36±7.13), t=8.02, P<0.01). Conclusion Antidepressant treatment can alleviate anxiety and/or depression, improve the clinical curative effect of refractory asthma and help to improve lung function. Key words: Anxiety; Depression; Refractory asthma; Flupentixol Melitracen